Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn’s disease

Published:February 06, 2019DOI:

      Background and Aims

      It is standard of care to perform ileocolonoscopy within a year of ileocolonic resection for Crohn’s disease (CD) and to guide management decisions based on the Rutgeert score (RS). The modified RS subdivides i2 into lesions confined to the anastomosis (i2a) or >5 aphthous lesions in the neoterminal ileum (i2b). There is uncertainty, however, if i2a lesions incur an increased risk of disease recurrence. The primary aim of this study was to compare the rates of endoscopic progression between i2a and i2b when compared with i0-i1.


      This was a retrospective, single-center study including patients with CD who had an ileocolonoscopy ≤12 months after ileocolonic resection with primary anastomosis and who had >1 year of documented clinical follow-up after the index endoscopic evaluation. All consecutive eligible patients between 2004 and 2014 were included in the study. Demographic, disease, and treatment data were collected. Patients with i3 or i4 at index colonoscopy were excluded from further analyses. Outcomes included endoscopic progression and recurrent surgery. For patients with RS of i0 to i2, endoscopic progression was predefined as progression of the RS in subsequent colonoscopies to i3 or i4. Recurrent surgical interventions were defined as re-resection or stricturoplasty of the previous ileocolonic anastomosis.


      Two hundred seven CD patients (median age, 36 years [interquartile range, 26-48]) had an ileocolonoscopy ≤12 months after ileocolonic resection. At index colonoscopy, 95 patients (45.9%) had an RS of i0, 31 (14.9%) i1, 40 (19.3%) i2a, 25 (12.1%) i2b, 10 (4.8%) i3, and 6 (2.9%) i4. One hundred ninety-one patients had an RS of i0 to i2 and were included in the analyses for recurrent surgery. One hundred forty-nine patients had a second endoscopic evaluation and were included in the analysis for the primary outcome of endoscopic disease progression. Kaplan-Meier analyses were performed and found the hazard ratio (HR) of endoscopic progression to be significantly higher with i2b lesions when compared with i0 or i1 (HR, 6.22; 95% confidence interval [CI], 2.38-16.2; P = .0008). Patients with i2a did not have significantly higher rates of endoscopic progression when compared with i0 or i1 (HR, 2.30; 95% CI, .80-6.66; P = .12). Likewise, patients with i2b lesions had higher risk of needing recurrent surgery when compared with i0 or i1 (HR, 3.64; 95% CI, 1.10-12.1; P = .034), whereas patients with i2a lesions were not found to have a significantly elevated risk of recurrent surgery (HR, 1.43; 95% CI, .35-5.77; P = .62).


      Endoscopic lesions limited to the ileocolonic anastomosis (RS i2a) in patients with CD undergoing colonoscopy within 1 year of their resection were not associated with a significantly higher rate of progression to more severe disease, whereas those in the neoileum (RS i2b) were. Prospective studies are needed to confirm these findings.


      CD (Crohn’s disease), CI (confidence interval), HR (hazard ratio), RS (Rutgeert score)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abraham C.
        • Cho J.H.
        Inflammatory bowel disease.
        N Engl J Med. 2009; 361: 2066-2078
        • Peyrin-Biroulet L.
        • Loftus Jr., E.V.
        • Colombel J.F.
        • et al.
        The natural history of adult Crohn's disease in population-based cohorts.
        Am J Gastroenterol. 2010; 105: 289-297
        • Rutgeerts P.
        • Geboes K.
        • Vantrappen G.
        • et al.
        Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery.
        Gut. 1984; 25: 665-672
        • Buisson A.
        • Chevaux J.B.
        • Allen P.B.
        • et al.
        Review article: the natural history of postoperative Crohn's disease recurrence.
        Aliment Pharmacol Ther. 2012; 35: 625-633
        • Lichtenstein G.R.
        • Loftus E.V.
        • Isaacs K.L.
        • et al.
        ACG clinical guideline: management of Crohn's disease in adults.
        Am J Gastroenterol. 2018; 113: 481-517
        • Rutgeerts P.
        • Geboes K.
        • Vantrappen G.
        • et al.
        Predictability of the postoperative course of Crohn's disease.
        Gastroenterology. 1990; 99: 956-963
        • Gionchetti P.
        • Dignass A.
        • Danese S.
        • et al.
        3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: surgical management and special situations.
        J Crohns Colitis. 2017; 11: 135-149
        • Sandborn W.J.
        • Feagan B.G.
        • Hanauer S.B.
        • et al.
        A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
        Gastroenterology. 2002; 122: 512-530
        • Domenech E.
        • Manosa M.
        • Bernal I.
        • et al.
        Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study.
        Inflamm Bowel Dis. 2008; 14: 508-513
        • Silverberg M.S.
        • Satsangi J.
        • Ahmad T.
        • et al.
        Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
        Can J Gastroenterol. 2005; 19: 5A-36A
        • Bayart P.
        • Duveau N.
        • Nachury M.
        • et al.
        Ileal or anastomotic location of lesions does not impact rate of postoperative recurrence in Crohn's disease patients classified i2 on the Rutgeerts score.
        Dig Dis Sci. 2016; 61: 2986-2992
        • Riviere P.
        • Vermeire S.
        • Irles-Depe M.
        • et al.
        No change in determining Crohn's disease recurrence or need for endoscopic or surgical intervention with modification of Rutgeerts' scoring system.
        Clin Gastroenterol Hepatol. 2019; 17: 1643-1645
        • Modigliani R.
        • Mary J.Y.
        • Simon J.F.
        • et al.
        Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives.
        Gastroenterology. 1990; 98: 811-818
        • Gajendran M.
        • Bauer A.J.
        • Buchholz B.M.
        • et al.
        Ileocecal anastomosis type significantly influences long-term functional status, quality of life, and healthcare utilization in postoperative Crohn's disease patients independent of inflammation recurrence.
        Am J Gastroenterol. 2018; 113: 576-583
        • Anyane-Yeboa A.
        • Yamada A.
        • Haider H.
        • et al.
        A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease.
        Aliment Pharmacol Ther. 2018; 48: 933-940
        • Regueiro M.
        • Feagan B.G.
        • Zou B.
        • et al.
        Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection.
        Gastroenterology. 2016; 150: 1568-1578
        • Marteau P.
        • Laharie D.
        • Colombel J.F.
        • et al.
        Interobserver variation study of the Rutgeerts score to assess endoscopic recurrence after surgery for Crohn's disease.
        J Crohns Colitis. 2016; 10: 1001-1005

      Linked Article

      • Postoperative Crohn’s disease management: still learning and evolving
        Gastrointestinal EndoscopyVol. 90Issue 2
        • Preview
          Despite advancement in the treatment of Crohn’s disease since the introduction of the first biologic in the late 1990s, Crohn’s disease remains a chronic and often relapsing and remitting disease.1 It is estimated that nearly half of patients will require a bowel resection within the first two decades from the time of diagnosis, and an ileocolic resection remains the most common surgical procedure performed.2,3 Postoperative disease recurrence is common, and the management of such adverse events remains a challenging clinical question for clinicians.
        • Full-Text
        • PDF